105 results about "Immuno histochemistry" patented technology

The present disclosure provides isolated antibodies that specifically bind to human PD-L1, as well as antigen binding fragments of such antibodies, and kits comprising the anti-PD-L1 antibodies or binding fragments and a set of reagents for detecting a complex of the antibody, or antigen binding fragment thereof, bound to human PD-L1. The antibodies and antigen binding fragments of this disclosure are useful for immunohistochemical detection of human PD-L1 expression in tissue samples. Nucleic acid molecules encoding the antibodies and antigen binding fragments of this disclosure, as well as expression vectors and host cells for expression thereof, are also provided.

The present invention describes a method utilizing a set of genes or gene products whose altered expression in cancer tissue, particularly head and neck cancer and other carcinomas, or its adjacent normal tissues predicts (a) probability of recurrence in time after treatment (b) sensitivity or resistance to therapies or (c) probability of metastasis at the time of initial discovery of the tumor. Furthermore, the invention describes methods of determining the molecular signature in tumor tissues, tissues adjacent to the tumor, or in saliva by using DNA microarray techniques, quantitative real-time PCR, immunohistochemistry or other methods that are used for determining gene or gene product expression levels.

Methods and apparatuses for gently removing embedding media from biological samples at temperatures below the embedding medium melting point with liquid composition using batch methods or automated instruments prior to immunohistochemical (IHC), in situ hybridization (ISH) or other special staining or histochemical or cytochemical manipulations.

The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.

The invention discloses a double-stained kit for auxiliary diagnosis of benign or malignant hepatocellular tumor and application thereof. The kit comprises the following components: mixed primary antibody of Arginase-1 and Glypian-3, mixed second antibody of alkaline phosphatase conjugated goat anti-rabbit second antibody and horse radish peroxidase labeled goat anti -mouse second antibody, chromogenic reagent AP-Red and DAB (Diaminobenzidine), and TBS (Tris buffer saline) buffer solution. Two immunohistochemical labels provided by the invention are used for auxiliary diagnosis of benign or malignant hepatocellular tumor and differentiation degrees of tumor, the two labels are displayed through staining label by different detection systems and utilizing the differences of target cells stained by each label, information quantity and differential staining on the same radiograph are improved, readability and accuracy of radiograph reading are increased, so that the double-stained kit has important significance to identification of benign or malignant hepatocellular tumor and differentiation degrees of tumor.

The present invention provides compositions, kits, assembles of articles and methodology for carrying out processes that permit biological enzymes to act directly on metals and metal particles. In particular, the invention relates to use of enzymes to selectively deposit metal to the vicinity of a target molecule. The invention also relates to linking of metals to enzyme substrates, control of enzymatic metal deposition and applications of enzymatic metal deposition to sensitively and selectively detect target molecules such as biomarkers in various biological samples, such as chromogenic immunohistochemical (IHC) detection in situ by using bright field light microscope.

The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

The invention relates to the field of biological detection, provides an anti-CK20 protein monoclonal antibody, further provides a preparing method of the anti-CK20 protein monoclonal antibody, and further provides a hybridoma cell line for secreting anti-CK20 proteins. A heavy-chain variable region and a light-chain variable region of the antibody have the amino acid sequence shown in SEQ ID NO.4and the amino acid sequence shown in SEQ ID NO.5. The 411th-site to 424th-site proteins of the human CK20 amino acid are selected to be coupled with KLH to form an immunogen. The cell line is a rat hybridoma cell line 10F6B12A9 and has the preservation number of CGMCC NO.16204. The anti-CK20 protein monoclonal antibody has high specificity and sensitivity, can specifically recognize cells of expressing CK20 proteins, and is suitable for immunological detection, especially immuno-histochemistry.

The invention discloses a tumor necrosis factor-alpha induced protein 8 L3 (TIPE3) immunohistochemistry detection kit for diagnosing lung cancer. Contents of the kit comprise a reagent which is used for inactivating endogenous peroxidase and biotin in a human tissue section, a non-specific protein blocking agent which is used for blocking non-specific staining of cross protein reaction in the human tissue section, a rabbit anti-human initial antibody which is combined with human tissue antigen, an antibody diluent, a goat anti-rabbit monoclonal connection antibody which can be connected with the initial antibody and is marked by horse radish peroxidase, a developing reagent which can be reacted with the horse radish peroxidase and used for developing, and a reagent which can specifically stain nuclei in tissues. TIPE3 is positively expressed in various kinds of pathological type lung cancer, tumors can be early detected and found, the kit is high in specificity and high in sensitivity and can be applied to early diagnosis of the lung cancer, a patient can be effectively and timely treated, unnecessary medical cost is reduced, the survival quality of the patient is improved, survival time is prolonged, and the survival rate of the patient who suffers from the lung cancer is improved.

The invention discloses an MSI prediction model construction method based on gastric cancer histopathological image texture features. The method comprises the following steps: obtaining histopathological images of a gastric cancer patient, marks of focus parts and clinical pathological information; extracting texture features of the original image and texture features after wavelet transform for the histopathological image of the patient with gastric cancer; performing feature selection on the obtained texture features by using LASSO, and selecting non-zero coefficient features corresponding to the lambda value when 10 times of cross validation error is minimum to obtain screened texture features; carrying out linear fitting according to the characteristic value of the selected texture characteristic and the coefficient weight of the characteristic value so as to obtain an MSI label of the gastric cancer patient; and combining the MSI label and the clinical pathological information ofthe patient to construct an MSI prediction model. According to the method, the MSI state of the gastric cancer patient is directly predicted on the basis of the histopathological image which is easy to obtain, an additional laboratory is not required to carry out gene detection and immunohistochemical analysis, and the MSI state can be detected at a lower cost.

The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.

The invention discloses a reagent for auxiliarily diagnosing lung cancer lymph node metastasis, comprising 8 antibodies which are used for detecting 8 protein markers which are MMP1 (matrix metalloproteinase-1), TIMP1 (tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1), IQGAP1 (IQ motif containing GTPase activating protein 1), TPX2 (targeting protein for Xklp2), uPA (Urokinase-type plasminogen activator), Cathepsin-D, Fascin and pIgR/SC (polymeric immunoglobulin receptor/secretory component). By adopting the 8 antibodies and an immunohistochemical staining result, lung cancer lymph node metastasis can be auxiliarily diagnosed, and the reagent is expected to be used for the risk estimation of lung squamous cell cancer lymph node metastasis and the prognostic prediction. The reagent has high creditability, strong practicability and clinical use value based on the clinical routine immunohistochemical staining technology when the reagent is used for auxiliary diagnosis.

The invention belongs to the technical field of immunohistochemistry and relates to a double-labeled immunohistochemical staining kit for micro invasive lung adenocarcinoma. In order to solve the problem that invasive components and non-invasive components of micro invasive lung adenocarcinoma in HE staining films are difficultly distinguished clearly, the CD34 and beta-Tubulin-III double-labeled immunohistochemical staining kit is prepared and is applied to identification of the invasive lesions and the non-invasive components in the early stage of the lung adenocarcinoma, and overdiagnosis or under-diagnosis of the lung adenocarcinoma, caused by artificial interpretation difference, can be avoided.

The invention discloses an experimental method of effects of DNA oxidative damage and bone cell apoptosis on avascular necrosis, the method comprises the following steps: experimental grouping and establishment of an animal model, preparation of specimens, histomorphology observation under a light microscope, observation by a transmission electron microscope, bone cell apoptosis situation detection by TUNEL (terminal dexynucleotidyl transferase(TdT)-mediated dUTP nick end labeling) method, bone marrow hematopoietic cell DNA oxidative damage detection by monoclonal antibody N45.1 immunohistochemistry method, and statistical analysis. According to the method, experiment animals are respectively killed in the second week and the fourth week after the last time of administration, and five animals are killed for each time in each group; bilateral femoral heads are taken for conventional fixed decalcification for stand-by testing, the number of vacant bone lacunas is counted by HE (hematoxylin-eosin) staining, the bone cell morphological change is observed by the electron microscope, the bone cell apoptosis situation is detected by the TUNEL method, the bone marrow hematopoietic cell DNA oxidative damage is detected by the immunohistochemistry method, and the relationship between SANFH ((steroid-induced avascular necrosis of femoral head)) and the bone marrow hematopoietic cell DNA oxidative damage and the bone cell apoptosis is explored, and provides new ideas for the further study of pathogenesis of the steroid induced avascular necrosis of femoral head.

The invention relates to an immunohistochemical kit for rapidly identifying a lung cancer and sclerotic lung cytoma in an operation. The kit comprises a frozen stationary liquid, a peroxidase sealingagent, a CK wide (AE1/AE3) antibody, a P40 antibody, a TTF1 antibody, a VIM antibody, an enzyme-labeled goat anti-mouse/rabbit polymer, a DAB chromogenic substrate, a DAB chromogenic buffer solution,a hematoxylin redyeing solution and a cleaning buffer solution, and the invention also provides a use method of the immunohistochemical detection kit. According to the kit, quick immunohistochemical staining is carried out on frozen sections in the operation; CK wide, VIM, TTF1 and p40 detection indexes are used for assisting in distinguishing the sclerotic lung cytoma and the lung cancer; and anintraoperative pathological judgment basis is increased from single morphological HE staining to combination of immunohistochemistry and morphology, and a comprehensive and reliable diagnosis basis isprovided for pathologists so that diagnosis accuracy is improved, and a misdiagnosis rate and a missed diagnosis rate are reduced.

The invention discloses a constructing method of a bracket-free engineering cartilaginous tissue and a product therefrom. The constructing method comprises the following steps: inducing and differentiating human umbilical mesenchymal stem cells into cartilaginous cells and then carrying out aggregation inducing culture so that the cartilaginous cells excrete stroma towards the outside of cells and form membranoid substance; continuously inducing and culturing the membranoid substance in a cell culture box and then transferring the membranoid substance into a centrifugal tube for inducing culture to form loose cartilaginous tissue agglomerate; and continuously inducing and culturing the loose cartilaginous tissue agglomerate in a rotating wall type bioreactor to obtain dense cartilaginous-like tissue. The cytology, the histology or the immunohistochemistry dyeing shows that the constructed engineering tissue has a normal cartilaginous cell type. The constructed bracket-free engineering cartilaginous tissue does not relate to the composite problem of the cells and an exogenous bracket, is absent from the biocompatibility problem between the cells and the bracket, is safe to human body, has even cell planting density and simple clinical application operation and can be applied to the treatment or the repair of cartilage loss.

The invention discloses a method for researching the effects of Dickkopf-1 and cell apoptosis in steroid-induced avascular necrosis of femoral head (SANFH). The method comprises the following steps: by taking the femoral head sample of SANFH taken through total hip replacement as an experiment group and taking the sample after the hip replacement for fracture of neck of femur as a contrast group, cutting the femoral head sample, fixing and decalcifying the cut femoral head sample to prepare slices, observing the morphologic change of osteocytes by an electronic microscope, observing the pathological change of the osteocytes by a light microscope, counting the vacant bone lacuna, detecting the expression of Dickkopf-1 by an immunohistochemical staining technique, thus exploring the effects of Dickkopf-1 and cell apoptosis in SANFH. The method can be used for providing assistance for early diagnosis and curing of SANFH and also providing a theoretical basis for clinical prevention and curing of SANFH in future.

The invention relates to the technical field of medical biological detection and provides novel uses of WDR1, NMI and LIN28 proteins, particularly an application in preparation of a kit for assessingbrain glioblastoma prognosis. The invention further provides a kit and detection method performing brain glioblastoma prognosis assessing through quantitative detection of the WDR1, NMI and LIN28 proteins by adopting an immunohistochemical method. Expression levels of the WDR1, NMI and LIN28 proteins in brain glioblastoma tissues are measured by utilizing an immunohistochemical technique and system scoring, and it is determined that the expression levels of the WDR1, NMI and LIN28 proteins are related with prognosis of patients with brain glioblastoma after operations by combination with postoperative follow-up observation information. The combination of the WDR1, NMI and LIN28 proteins can be used for preparing a protein molecular marker for determining prognosis of patients with brain glioblastoma, and is of great directive significance for brain glioblastoma molecular subtyping, postoperative monitoring of patients and sequential therapy.

The invention relates to the field of biological detection, and provides an anti-MSH2 protein monoclonal antibody. A heavy-chain variable area and a light-chain variable area of the anti-MSH2 proteinmonoclonal antibody have the amino acid sequences of SEQ ID NO.2 and SEQ ID NO.3 respectively. The invention further provides a preparing method of the anti-MSH2 protein monoclonal antibody. The 411thto 424th proteins of a human MSH2 amino acid are selected to be coupled with KLH to form an immunogen. The invention further provides a hybridoma cell line for secreting the anti-MSH2 protein. The cell line is a rat hybridoma cell line 1B11-14-16 and has the preservation number of CGMCC NO.17405. The anti-MSH2 protein monoclonal antibody has high specificity and sensitivity, can specifically recognize cells for expressing the MSH2 proteins and is suitable for immunological detection, especially immuno-histochemistry.

The invention discloses a marker of PPP1CA for liver cancer diagnosis as well as prognosis detection and application thereof. The marker has the advantages that the expression of PPP1CA in tissues of a liver cancer patient is detected in an immuno-histochemical way through RT-PCR and Western Blot; compared with non-cancer tissues, the expression level and protein level of PPP1CA gene are obviously increased; by utilizing ELISA or an immunochemistry luminescence method to detect the content of PPP1CA in the blood, compared with a common person, the content of PPP1CA in the serum of the liver cancer patient is obviously increased; after analysis indicating, the increasing of expression level of PPP1CA in the tissue or blood sample is closely related to the generation and development of the liver cancer; the 5-year survival period of the liver cancer patient with high expression level of PPP1CA is shortened; the liver cancer can be performed with diagnosis and prognosis judging through detecting the content of PPP1CA in the tissue or blood sample; the marker and the method with higher sensitivity and stronger specificity are provided for the clinical diagnosis and the prognosis judging and treatment.